Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECVAX-NEO1 added to neoadjuvant anti-PD-1 therapy for triple-negative breast cancer
2024-512520-11-00Phase 2Authorised
- Sponsor
- NEC Corporation
- Start
- Nov 2024
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NECVAX-NEO1 in triple-negative breast cancer (TNBC), sponsored by NEC Corporation. Primary endpoints: Reported adverse events and serious adverse events and Changes from baseline in safety assessments. Planned start Nov 2024; status: authorised.
02
Drugs
NECVAX-NEO1
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-512520-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512520-11-00.